familymednews.com
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow that comprises 1 percent of all new cancer cases and almost 2 percent of cancer deaths in the U.S. The five-year survival rate for the disease is less than 20 percent. Researchers at the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore […]
Continue reading »
In a study published in Nature Communications, a team led IRCM Hematopoiesis and Cancer Research Unit director Tarik Möröy reveals how the GFI1 protein sometimes helps leukemia and lymphoma cancer cells evade therapy. This discovery could eventually help orient patients towards more effective treatment by considering the particular characteristics of their disease. In this Q&A, Möröy and his team offer […]
Continue reading »
A drug called dasatinib was found to be safe and effective for children with chronic myeloid leukemia, according to a clinical trial published in the Journal of Clinical Oncology. Based on the findings, the drug has been approved by the FDA and is now available for use in some pediatric patients. The study was co-authored by Nobuko Hijiya, MD, professor […]
Continue reading »
In a study published online today in Science Translational Medicine, Albert Einstein College of Medicine researchers report that an experimental peptide (small protein) drug shows promise against the often-lethal cancer acute myeloid leukemia (AML) and describe how the drug works at the molecular level. The findings have led to a Phase I/II clinical trial for patients with advanced AML and […]
Continue reading »
Around 600 children under the age of 15 are diagnosed with leukaemia each year in Germany. The effects are especially dramatic if this severe illness develops at birth or shortly afterwards. Research carried out at the Division of Genetics at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) has now revealed another molecular cause for a particularly aggressive type of leukaemia in infants. The results […]
Continue reading »